CClinicalTrials.gg
RecruitingNCT06951620Updated Jun 8, 2025

Optimizing Aerobic Fitness in Older Adults

An interventional study of HIIT and MICT in Aerobic Capacity and High Intensity Interval Training, sponsored by University of Vermont Medical Center. Recruiting at 1 site in United States. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2025-06-08.

Sponsored by University of Vermont Medical Center · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 5 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
114
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Study summary

Hospitalization and treatment for cardiovascular disease is one of the main contributors to disability in older adults. Moderate intensity continuous aerobic and resistance training have been the cornerstone of cardiac rehabilitation (CR) for decades to remediate hospital-acquired functional deficits, but some groups receive less or minimal functional benefit from this training. The proposed studies seek to optimize recovery of aerobic fitness and physical function among older cardiac patients using a novel high intensity training regimen with the long-term goal of reducing subsequent disability and improving clinical outcomes.

Read the detailed description

Clinical events and hospitalization often initiate disability in older adults with cardiovascular disease (CVD) being the primary cause of hospital acquired disability. Cardiac rehabilitation (CR) was designed to correct this disability, with moderate intensity, continuous aerobic training (MICT) as its foundation but some patients, including older adults, receive less functional benefit from MICT. Attention has recently focused on high intensity interval aerobic training (HIIT) as an alternative to MICT because it improves aerobic fitness to a greater extent and is safe and feasible for older adults enrolled in CR; however, neither HIIT nor MICT address age-related atrophy and weakness. Resistance training is a core component of CR meant to correct these deficits, but the moderate intensity resistance training (MIRT) most commonly used has minimal effects on these outcomes. Thus, there is an unmet clinical need for multi-modal exercise interventions that address the unique needs of older adult patients enrolled in CR to optimize improvements in functional recovery and clinical outcomes.

The investigators will conduct the first direct comparison of HIIT+HIRT to MICT+MIRT to improve VO2peak and physical function in older men and women enrolled in CR.

Aim 1: Determine the efficacy of combined HIIT+HIRT vs MICT+MIRT to increase VO2peak in older adult patients enrolled in CR Aim 2: Determine the efficacy of combined HIIT+HIRT vs MICT+MIRT to increase physical function in older adult patients enrolled in CR.

02

Conditions studied

  • Aerobic Capacity
  • High Intensity Interval Training

Keywords

  • cardiac rehabilitation
  • HIIT
  • MICT
  • exercise in older adults
  • aerobic capacity
03

In context

Lead sponsor

University of Vermont Medical Center is the lead sponsor of 41 studies on the registry; 19 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • >65 years old
  • ambulatory
  • enrolled in CR at our center following a recent clinical diagnosis of myocardial infarction or percutaneous intervention will be recruited

Exclusion criteria

Exclusion Criteria:

  • have an active malignancy (excluding non-melanoma skin cancer or low grade prostate cancer under surveillance)
  • unwilling to comply with the exercise prescription they may be assigned to
  • have a submaximal performance on entry exercise tolerance test, defined as respiratory exchange ratio \<1.0
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Care provider, Investigator, Outcomes assessor)
Enrollment
114 participants (estimated)

Study arms

  • Experimental
    Intervention Group

    Patients who recently experienced a myocardial infarction (MI) or percutaneous intervention (PCI; angioplasty, stent placement or valve replacement) and enroll in Phase 2 Cardiac Rehabilitation (CR) may be randomized to High intensity training

    Other: HIIT

  • Experimental
    Usual Care Group

    Patients who recently experienced a myocardial infarction (MI) or percutaneous intervention (PCI; angioplasty, stent placement or valve replacement) and enroll in Phase 2 Cardiac Rehabilitation (CR) may be randomized to Moderate intensity training

    Other: MICT

Interventions

  • OtherHIIT

    Patients who recently experienced a myocardial infarction (MI) or percutaneous intervention (PCI; angioplasty, stent placement or valve replacement) and enroll in Phase 2 Cardiac Rehabilitation (CR) may be randomized to High intensity training (HIIT)

  • OtherMICT

    Patients who recently experienced a myocardial infarction (MI) or percutaneous intervention (PCI; angioplasty, stent placement or valve replacement) and enroll in Phase 2 Cardiac Rehabilitation (CR) may be randomized to Moderate intensity training

06

What researchers measure

Primary outcomes

  1. Change in Aerobic fitness

    Changes in fitness level (peak oxygen uptake) will be measured from intake to completion of the intervention (4 months after intake).

    Time frame: Within 4 months of the intake assessment

  2. Change in 30 sec sit-to-stand test (STS)

    Changes in STS will be measured from intake to completion of the intervention (4 months after intake).

    Time frame: Within 4 months of the intake assessment

Secondary outcomes

  1. Changes in Quality of Life- Cardiac Specific

    Changes in perceived quality of life (MacNew) questionnaires will be measured from intake to completion of the intervention (4 months after intake). The MacNew Heart Disease Health-Related Quality of Life Questionnaire was used. Scores range from 1 to 7, with higher scores indicating better outcomes.

    Time frame: Within 4 months of the intake assessment

  2. Changes in Depressive Symptoms

    Changes in reported depressive symptoms. The Patient Health Questionnaire (PHQ-9) will be measured from intake to completion of the intervention (4 months after intake). Scores range from 0-27 with higher scores associated with severity of depression

    Time frame: Within 4 months of the intake assessment

  3. Changes in Executive Function (digit span)

    Changes in Executive function (digit span) will be measured from intake to completion of the intervention (4 months after intake). The Digit Span subtest of the Wechsler Adult Intelligence Scale-IV (WAIS-IV) was used. Scores range from 1 to 19, with higher scores indicating worse outcomes.

    Time frame: Within 4 months of the intake assessment

  4. Changes in Executive Function (BRIEF)

    Changes in self-reported Executive function problems (BRIEF) will be measured from intake to completion of the intervention (4 months after intake). The Global Executive Composite (GEC) of the Behavior Rating Inventory of Executive Function (BRIEF) was used. T-scores are reported. A T-score of 50 indicates the population mean, and 10 is the standard deviation. Higher T-scores indicate worse outcomes. T-scores above 65 indicate clinically significant problems.

    Time frame: Within 4 months of the intake assessment

  5. Changes in Executive Function (trail making)

    Changes in Executive function (Trail making task) will be measured from intake to completion of the intervention (4 months after intake). The Trail-Making subtest of the Delis-Kaplan Executive Function System (D-KEFS) was used. Scores range from 1 to 19, with higher scores indicating worse outcomes.

    Time frame: Within 4 months of the intake assessment

  6. Changes in Physical Function (Six Minute Walk Test)

    Changes in 6MWT will be measured from intake to completion of the intervention. Distance walked in meters (m) will be recorded.

    Time frame: Within 4 months of the intake assessment

  7. Changes in Enjoyment of Exercise (PACES)

    Changes in Enjoyment of Exercise will be assessed with the validated Physical Activity Enjoyment Scale and will be measured from intake to completion of the intervention. THe score ranges from 0-48 and score below 24 is interpreted as lower enjoyment of physical activity

    Time frame: Within 4 months of the intake assessment

  8. Changes in Anxiety

    Changes in reported anxiety symptoms. The Generalized Anxiety Disorder questionnaire will be measured from intake to completion of the intervention. Rated from 0-7, the higher the score the more anxious

    Time frame: Within 4 months of the intake assessment

Other outcomes

  1. Maintenance of Fitness Following Intervention

    Changes in fitness level (peak oxygen uptake) will be measured from intervention completion until follow-up (8 months after intervention completion).

    Time frame: From completion of intervention (4 months) to follow-up (26 weeks).

07

Study locations

1 of 1 sites recruiting
  • UVMMC Cardiac Rehabilitation
    South Burlington, Vermont 05403, United States
    • Sheena Barnes Clinic Supervisor · Contact · sheena.barnes@uvmhealth.org · 802-847-4600
    • Sherrie Khadanga PI, MD · Principal investigator
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06951620
Lead sponsor
University of Vermont Medical Center
Collaborators
National Institute on Aging (NIA)
Responsible party
Sherrie Khadanga (Principal Investigator, University of Vermont Medical Center) — Principal investigator
First posted
Apr 30, 2025
Start date
Apr 17, 2025
Primary completion
Mar 15, 2029 (estimated)
Completion
Jun 30, 2029 (estimated)
Last update
Jun 8, 2025

Study contacts

Patrick Savage, Research Coordinator
Contact
patrick.savage@uvmhealth.org
802-847-4545
Sherrie Khadanga MD, Principal Investigator, MD
principal investigator · University of Vermont Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion